SCHEDULE: Tudor Investment Corp. Divests scPharmaceuticals Stake

Tudor Investment Corporation and Paul T. Jones II have reported divesting their beneficial ownership in scPharmaceuticals Inc., reducing their stake to 0%.

Summary

• Tudor Investment Corporation and Paul T. Jones II, previously deemed to beneficially own more than 5% of scPharmaceuticals Inc. common stock, now report 0% beneficial ownership.
• The filing is a Schedule 13G, indicating a change in reportable beneficial ownership.
• The event requiring this filing occurred on October 6, 2025, when the reporting persons may have been deemed to beneficially own more than 5% of the outstanding common stock.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment of a significant stake by a major institutional investor is generally perceived as a negative signal for the issuer, suggesting a potential loss of confidence or a shift in investment strategy regarding the company.

Negatives

• Tudor Investment Corporation and Paul T. Jones II, previously significant beneficial owners (over 5%), have reduced their stake to 0%.
• The complete divestment by a major institutional investor could signal a lack of confidence in scPharmaceuticals Inc.'s future prospects.

Risks

• Potential negative market perception and investor confidence impact due to the complete divestment of a significant stake by a major institutional investor.
• Increased potential for stock price volatility as the market processes the implications of a large investor's exit.

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure of a change in institutional ownership, which can influence market sentiment for a company, particularly in the biotechnology or pharmaceutical sector where investor confidence is crucial.

Stakeholder Impact

• Shareholders may react negatively to the news of a significant institutional investor divesting their entire reportable stake, potentially leading to a decrease in share price.
• Potential impact on investor confidence and perception of the company's future prospects.

Key Dates

Recommendation

The complete divestment of a previously significant stake (over 5%) by a major institutional investor like Tudor Investment Corporation typically signals a loss of confidence or a strategic shift away from the company. This action by a sophisticated investor can be interpreted as a strong negative indicator, suggesting that the stock may face downward pressure or that the company's fundamentals are deteriorating. Without additional positive catalysts, this event warrants a 'sell' recommendation for investors to mitigate potential losses.

Keywords

scPharmaceuticals, Tudor Investment Corporation, Paul T. Jones II, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Common Stock